BioSpace News Archive

Meridian’s COVID-19 testing being deployed via its national lab & provider networks Todos’ portfolio of COVID-19 PCR and antibody testing solutions facilitates national scale Todos to equip Meridian mobile laboratories to complement existing labs

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious lung diseases, today announced that the company has been added to the Russell 3000 ® and Microcap ® Indexes at the conclusion of the Russell indexes annual reconstitution, effective upon the U.S. market open today. Annual Russell indexes reconstitution captures the 4,000 largest U.S. stock

Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it has been added to the Russell 3000 ® Index at the conclusion of the Russell indexes annual reconstitution, effective upon the U.S. market open today, June 29, 2020. Annual Russell indexes reconstitution captures the 4,000 largest U.S. stocks as of May 8

Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced two presentations at the upcoming International Society on Thrombosis and Haemostasis (ISTH) Virtual Congress being held from July 12-14, 2020. Presentation details: Poster Title: Phase 1 study to evaluate the pharmacokinetics, pharmacodynamics, and safety of ascending doses of subcutaneous marzeptacog alfa (activated) in adult subjects with hemophilia (PB0941)

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced that it has been added to the Russell 3000® Index at the conclusion of the Russell indexes annual reconstitution, effective upon the U.S. market open today, June 29, 2020. Russell indexes are widely used by investment managers and institutiona

Catalyst Biosciences, Inc. (NASDAQ:CBIO), today announced that it has been added to the Russell 2000 ® Index effective at the U.S. market open today, June 29, 2020. The Annual Russell index reconstitution captures the 4,000 largest US stocks as of May 8, ranking them by total market capitalization. Membership in the U.S. Russell 2000 Index ® remains in place for one year and also means automatic inclusion in the appropriate gro

SubioMed, Inc. (“SubioMed™” or the “Company”), a pioneer in the invention and development of disruptive Suspension Biomechanics™ technology addressing critical elements of gait and balance, today announced that it has appointed veteran MedTech industry leader Gary Peterson, to the position of Chief Executive Officer.

BioCardia®, Inc. , (OTC: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced that the Company has resumed cases in the CardiAMP Heart Failure Trial. The first patient procedure completed since elective procedures were paused due to COVID-19 took place at Morton Plant Hospital in Clearwater, Florida this month. New consents have also taken place at additional centers.

Emmaus Life Sciences, Inc. (OTCQB: EMMA) , a leader in sickle cell disease treatment, announced today that it was issued a license from the Israeli Ministry of Health on June 17, 2020 granting marketing authorization for the commercial distribution and sale of Endari® in Israel. Endari® is approved in Israel as in the U.S. as an amino acid indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients

Study demonstrated inhibiting phosphodiesterase-1 with ITI-214 in patients with heart failure improved cardiac function by enhancing cardiac contractility and dilating systemic arteries without inducing abnormal heart rhythms.